ID   RPCI-WM1
AC   CVCL_M087
SY   Roswell Park Cancer Institute-Waldenstrom Macroglobulinemia 1
DR   cancercelllines; CVCL_M087
DR   Cosmic; 2645646
DR   Wikidata; Q54951135
RX   PubMed=22812491;
RX   PubMed=22950966;
RX   PubMed=25853860;
RX   PubMed=28548645;
CC   Doubling time: ~34 hours (PubMed=22812491).
CC   Sequence variation: Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=22812491).
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 18
//
RX   PubMed=22812491; DOI=10.3109/10428194.2012.713481; PMCID=PMC4406272;
RA   Chitta K.S., Paulus A., Ailawadhi S., Foster B.A., Moser M.T.,
RA   Starostik P., Masood A., Sher T., Miller K.C., Iancu D.M., Conroy J.,
RA   Nowak N.J., Sait S.N.J., Personett D.A., Coleman M., Furman R.R.,
RA   Martin P., Ansell S.M., Lee K., Chanan-Khan A.A.;
RT   "Development and characterization of a novel human Waldenstrom
RT   macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute --
RT   Waldenstrom Macroglobulinemia 1.";
RL   Leuk. Lymphoma 54:387-396(2013).
//
RX   PubMed=22950966; DOI=10.3109/10428194.2012.727418;
RA   Drexler H.G., Chen S., MacLeod R.A.F.;
RT   "Would the real Waldenstrom cell line please stand up?";
RL   Leuk. Lymphoma 54:224-226(2013).
//
RX   PubMed=25853860; DOI=10.1371/journal.pone.0122338; PMCID=PMC4390194;
RA   Paulus A., Chitta K.S., Wallace P.K., Advani P.P., Akhtar S.,
RA   Blake M.K.K., Ailawadhi S., Chanan-Khan A.A.;
RT   "Immunophenotyping of Waldenstroms macroglobulinemia cell lines
RT   reveals distinct patterns of surface antigen expression: potential
RT   biological and therapeutic implications.";
RL   PLoS ONE 10:E0122338-E0122338(2015).
//
RX   PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884;
RA   Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y.,
RA   Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y.,
RA   Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.;
RT   "Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or
RT   CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through
RT   upregulation of Bcl-2 and AKT resulting in vulnerability towards
RT   venetoclax or MK2206 treatment.";
RL   Blood Cancer J. 7:e565.1-e565.11(2017).
//